Skip to main content
Clinical Trials/NCT03631004
NCT03631004
Completed
Phase 2

Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients

Instituto do Cancer do Estado de São Paulo1 site in 1 country100 target enrollmentStarted: October 1, 2018Last updated:

Overview

Phase
Phase 2
Status
Completed
Sponsor
Instituto do Cancer do Estado de São Paulo
Enrollment
100
Locations
1
Primary Endpoint
incidence of postoperative nausea and vomiting

Overview

Brief Summary

Olanzapine has been used as prophylactic antiemetic for chemotherapy induced nausea and vomiting.

The project aims to evaluate the efficacy of olanzapine in combination with ondansetron and dexamethasone in patients at high risk of postoperative nausea and vomiting, with previous history of nausea and vomiting induced by prior chemotherapy, submitted to medium and large surgery.

Detailed Description

Double blinded randomized clinical trial. Fifty patients will be selected for each group. Group A will receive 10mg olanzapine in the preoperative and group B will receive placebo in the preoperative period. Both groups will receive intravenous general anesthesia combined with epidural. All patients will receive epidural PCA.

The primary outcome of this study is the incidence of post-operative nausea and vomiting. The power of analysis was based on the following parameters: type error I (α = 0.05), error II (β = 0.8), 95% confidence interval and hypothesis test two-tailed. Thus, 42 patients are indicated per group to obtain reduction of the incidence of nausea and / or vomiting of the population risk from 60% to 30%. The population will be composed of 100 patients because it is assumed that percentage of loss of 10% per group.

The statistical analysis will be performed in program R version 3.5.1. The results obtained will be presented as mean + standard deviation for continuous data or absolute frequency for described data.

For quantitative variables, the Student's t-test will be used for with normal distribution or Mann-Whitney for non-distributed data normal.

For qualitative variables, the chi-square test will be used or Fisher's exact test. Significant difference is defined as p, 0.05.

Data will be collected and managed using REDCap data capture tools

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

olanzapine tablets

Experimental

PATIENT WILL TAKE OLANZAPINE 10 MG, 1 hour BEFORE SURGERY

Intervention: Olanzapine (Drug)

Starch tablets

Placebo Comparator

PATIENT WILL TAKE PLACEBO 1 hour BEFORE SURGERY

Intervention: Olanzapine (Drug)

Outcomes

Primary Outcomes

incidence of postoperative nausea and vomiting

Time Frame: 0-24 hours

nausea and vomiting/ retching (dichotomous variable)

Secondary Outcomes

  • incidence of side effects(24-48 hours)
  • incidence of postoperative nausea and vomiting(24-48 hours)
  • incidence of postoperative vomiting/retching(24-48 hours)
  • incidence of postoperative nausea(24-48 hours)
  • incidence of severe PONV(24-48 hours)
  • incidence of nausea severity(24-48 hours)

Investigators

Sponsor
Instituto do Cancer do Estado de São Paulo
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials